Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease, with a primary focus on pulmonary arterial hypertension (PAH). The IKT news feed highlights the company’s progress as it advances its lead investigational therapy, IKT-001, a prodrug of imatinib mesylate, through late-stage clinical development in PAH.
Visitors to this page can review company-issued press releases and related disclosures that describe Inhibikase’s clinical plans, regulatory interactions, and corporate developments. Recent news has covered the evolution of the IMPROVE-PAH clinical program for IKT-001, including the transition from a planned Phase 2b trial to a global pivotal Phase 3 study design following a Type C interaction with the U.S. Food & Drug Administration. The company also reports on its financial results, capital raises through private placements and underwritten public offerings, and changes in senior leadership and board composition.
Because Inhibikase is a clinical-stage company with no marketed products, its news flow is closely tied to research and development milestones, such as study protocol finalization, anticipated trial initiation timelines, and updates on the design of adaptive clinical studies in PAH. Corporate updates, including executive appointments and governance matters, are also reflected in its announcements. Investors and observers can use this news page to follow how Inhibikase describes the advancement of IKT-001 in pulmonary arterial hypertension and how the company positions itself within the cardiopulmonary disease space.
Inhibikase Therapeutics (IKT) reported a net loss of $4.49 million, or $0.18 per share, for Q3 2022, compared to a loss of $4.47 million in Q3 2021. The company faces an FDA clinical hold on its IkT-148009 programs for Parkinson's and Multiple System Atrophy but reports no serious adverse events in its Phase 2a trial. R&D expenses decreased to $2.98 million from $3.15 million year-over-year. Inhibikase plans to initiate a bioequivalence study for IkT-001Pro in Q4 2022 and continues to present its findings at industry conferences.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced it will report its financial results for Q3 2022 after market close on November 14, 2022. A conference call will follow on November 15, 2022, at 8:00 a.m. ET, to discuss the results and provide corporate updates. The company focuses on developing therapeutics for Parkinson's disease and related disorders, with its lead program, IkT-148009, targeting neurodegeneration.
Inhibikase Therapeutics (Nasdaq: IKT) announced a clinical hold from the FDA on its IkT-148009 programs targeting Multiple Systems Atrophy (MSA) and Parkinson's disease (PD). The FDA's hold was communicated via email, with an official letter expected within 30 days. CEO Milton H. Werner stated there have been no serious adverse events in the ongoing trials and emphasized the company's commitment to addressing the FDA's concerns. Inhibikase focuses on developing treatments for neurodegenerative diseases, particularly those related to Parkinson's.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced CEO Milton Werner will present at the Inaugural Neurodegeneration Targets Conference on October 20, 2022, in Boston. The presentation titled ABL Kinase Inhibition as a Disease-Modifying Therapy for Parkinson's Disease will cover pre-clinical studies of IkT-148009, suggesting its potential for multi-organ repair with daily oral therapy. This aligns with the ongoing Phase 2a '201' clinical trial, focusing on Parkinson's disease and related disorders. Inhibikase specializes in therapeutics targeting neurodegeneration, including GI tract issues.
Inhibikase Therapeutics (Nasdaq: IKT) announced that Dr. Milton Werner, CEO, will present at the Grand Challenges in Parkinson's Disease Conference on September 28-29, 2022, in Grand Rapids, Michigan. The presentation focuses on IkT-148009, a potential disease-modifying therapy for Parkinson's disease, detailing outcomes from multiple pre-clinical studies. The session will occur at 3:00 PM EDT on September 28, highlighting the therapy's impact on multi-organ repair. Inhibikase is dedicated to developing treatments for neurodegenerative disorders related to Parkinson's disease.
Inhibikase Therapeutics reported positive results for its investigational drug IkT-148009, demonstrating high systemic exposure and good CNS penetration in older adults and Parkinson's patients, with no significant adverse events. The company is actively enrolling patients in the Phase 2a '201' clinical trial aimed at treating untreated Parkinson's disease. The data, presented at the International Congress of Parkinson's Disease and Movement Disorders, supports IkT-148009's safety profile and its potential to protect neurons and improve quality of life for patients.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced its participation at the International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain, from September 15-18, 2022. CEO Milton Werner, Ph.D., will present the abstract titled "IkT-148009 as a potential disease-modifying therapy in PD" during the GPT 6 session on September 16, 2022, from 1:00 – 3:00 p.m. CEST. Inhibikase focuses on developing therapies for Parkinson's disease and related disorders, with their lead program targeting the Abelson Tyrosine Kinase pathway to potentially modify the disease's course.
Inhibikase Therapeutics (IKT) announced the appointment of Gisele Dion to its Board of Directors, effective September 1, 2022, as she succeeds retiring member Elizabeth O'Farrell. Dion, who has extensive experience in public companies, will chair the Audit Committee and serve on the Compensation Committee. Milton H. Werner, CEO, expressed optimism about Dion's expertise in finance and mergers, which can enhance Inhibikase's efforts in developing therapeutics for Parkinson's and related diseases. Her previous roles include senior positions at Takeda Pharmaceuticals and Shire Pharmaceuticals.
Inhibikase Therapeutics (Nasdaq: IKT) announced the FDA's clearance of its Investigational New Drug application for IkT-001Pro, aimed at treating Chronic Myelogenous Leukemia (CML). The SMP letter allows the initiation of a bioequivalence study to assess safety compared to imatinib, with preclinical data suggesting IkT-001Pro may be 3.4 times safer than imatinib. This prodrug formulation aims to enhance patient adherence and quality of life by reducing gastrointestinal side effects. Inhibikase's pipeline also includes treatments for Parkinson's and related disorders.
Inhibikase Therapeutics, Inc. (IKT) has announced the dosing of the first patient in its Phase 2a '201 trial' for IkT-148009, a c-Abl inhibitor aimed at treating Parkinson's disease. This trial involves 120 untreated patients and will evaluate safety, tolerability, and pharmacokinetics over 12 weeks. Preliminary animal studies suggested functional recovery could occur within eight weeks. The company anticipates increased patient enrollment as more trial sites become operational, highlighting its commitment to improving the lives of those affected by neurodegenerative diseases.